Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
23155-0778-72 23155-0778 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 June 15, 2022 No Longer Used
68788-8063-01 68788-8063 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Aug. 16, 2021 Oct. 30, 2023 No Longer Used
68788-8063-03 68788-8063 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Aug. 16, 2021 Oct. 30, 2023 No Longer Used
68788-8063-06 68788-8063 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Aug. 16, 2021 Oct. 30, 2023 No Longer Used
68788-8063-09 68788-8063 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Aug. 16, 2021 Oct. 30, 2023 No Longer Used
00003-3734-13 00003-3734 Nivolumab OPDIVO 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec. 8, 2017 In Use
00069-0135-01 00069-0135 Bosutinib monohydrate, Bosutinib Bosulif 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 4, 2012 In Use
00069-0136-01 00069-0136 Bosutinib monohydrate, Bosutinib Bosulif 500.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 4, 2012 In Use
00069-0193-01 00069-0193 Bosutinib monohydrate, Bosutinib BOSULIF 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 18, 2017 In Use
60505-6050-04 60505-6050 Bortezomib BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 Dec. 31, 2028 In Use

Found 10,000 results in 5 milliseconds — Export these results